Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Severe COVID-19 Infection (Danish Phase 2 Study)
2020-001459-42Phase 2Terminated
- Sponsor
- Zealand University Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ruxolitinib in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia, sponsored by Zealand University Hospital. Primary endpoint: 30-day mortality. Started Apr 2020; status: terminated.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001459-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001459-42.